- Login
- Register & Subscribe
- Language: EN FR DE
Finance, Grants, Deals
Smith & Nephew buys wound-care business
Saturday 1 December 2012
Smith & Nephew Plc of the UK has moved to strengthen its position in wound care with the acquisition for $782 million in cash of most of the assets of privately-held Healthpoint Biotherapeutics of Fort Worth, Texas, US. The acquisition was announced on 28 November 2012.
Location
United Kingdom
Sanofi in allergy deal with Selecta Biosciences
Wednesday 28 November 2012
Sanofi SA has entered a collaboration with Selecta Biosciences Inc in the US to develop immunotherapies for up to three different allergies.
Location
United States
MorphoSys in alliance with Lanthio Pharma
Tuesday 27 November 2012
MorphoSys AG has negotiated rights to exclusively license new peptide technology from privately-owned Lanthio Pharma BV in the Netherlands. MorphoSys will also make an equity investment in Lanthio as part of a Series A round. Figures weren’t disclosed.
Location
Germany
Algeta, Ablynx to evaluate conjugation technology
Wednesday 21 November 2012
Ablynx NV of Belgium and Algeta ASA of Norway have announced plans to investigate synergies between their technologies to find out whether there is scope to develop new therapies for cancer.
Location
Belgium
Interview: Pfizer assets in UK start-up
Tuesday 20 November 2012
At a time when Big Pharma is aggressively shedding research assets, venture capital firms with an appetite for risk are discovering new investment opportunities.
Location
United Kingdom
Meeting Report: Dealmakers discuss their experiences
Sunday 18 November 2012
Dealmaking is at the heart of business development. But not all deals are the same. At a meeting of Bio-Europe in Hamburg, Germany on 13 November, business development executives from four companies talked about deals that have transformed their companies.
Location
Germany
Novartis expands alliance with MorphoSys
Wednesday 7 November 2012
Novartis has expanded its strategic alliance with MorphoSys AG to incorporate the German company’s newest antibody library and antibody selection technologies. Financial terms were not disclosed.
Location
Germany
AZ invests $25 million in Regulus
Monday 5 November 2012
AstraZeneca Plc has bought $25 million worth of shares in Regulus Therapeutics Inc in parallel with that company’s initial public offering on the Nasdaq over-the-counter market. Regulus is developing therapies targeting microRNAs, short ribonucleic acid molecules.
Location
United States
J&J completes Genmab share purchase
Tuesday 16 October 2012
Johnson & Johnson Development Corp, a unit of Johnson & Johnson Inc, has completed the DKK 475 million ($82 million) purchase of 10.7% of the enlarged share capital of Genmab A/S as part of a previously announced collaboration.
Location
Denmark
Merck to pay AiCuris €110 million upfront for antiviral portfolio
Monday 15 October 2012
Merck & Co. Inc has agreed to pay €110 million upfront to AiCuris GmbH & Co of Germany to gain access to its medicines targeting human cytomegalovirus, including a candidate antiviral which has been given ‘fast track’ designation by the FDA.
Location
United States
Select a News Category
Recent Appointments
Pascale Witz to head strategic development at Sanofi
Monday May 6 2013
Srinivas Akkaraju joins Sofinnova Ventures
Monday May 6 2013
Vicente Anido nominated to Nicox board
Monday May 6 2013
Jeremy Farrar named director of the Wellcome Trust
Monday May 6 2013
Harry Kirsch becomes CFO at Novartis
Monday May 6 2013